SCHEMBL1633738

SCHEMBL1633738

NC(=O)c1cnc(N2CC3CN(S(=O)(=O)c4ccc(OC(F)(F)F)cc4)CC3C2)nc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 6/20 0.78
HDAC4 P56524 6/20 0.78
HDAC1 Q13547 6/20 0.78
HDAC7 Q8WUI4 6/20 0.78
HDAC2 Q92769 6/20 0.78
HDAC10 Q969S8 6/20 0.78
HDAC11 Q96DB2 6/20 0.78
HDAC8 Q9BY41 6/20 0.78
HDAC6 Q9UBN7 6/20 0.78
HDAC9 Q9UKV0 6/20 0.78
HDAC5 Q9UQL6 6/20 0.78
DPP4 P27487 1/20 0.44
LIPE Q05469 2/20 0.43
EPHX2 P34913 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
AKR1C3 P42330 1/20 0.43
EPHX1 P07099 2/20 0.41
GBA1 P04062 1/20 0.41
SCN9A Q15858 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014379 0.88 HDAC3 (1.00) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1012314 0.82 HDAC3 (0.56) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1012602 0.79 HDAC3 (0.77) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1011281 0.78 HDAC3 (0.77) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1012457 0.74 HDAC3 (0.80) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1617645 0.73 HDAC3 (0.75) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL8248010 0.71 HDAC3 (0.71) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL30484934 0.69 MEN1 (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7955680 0.69 MEN1 (0.60) HDAC3HDAC4HDAC1HDAC7HDAC2
Trifluoroacetic Acid SCHEMBL30482769 0.69 MEN1 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932246-B2 Histone deacetylase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-04-26 US disclosed
US-20100152155-A1 Histone Deacetylase Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152155-A1 Histone Deacetylase Inhibitors HDAC1, HDAC2, HDAC11 HDAC3 6/4885HDAC4 7/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.